Back to Search
Start Over
Treatment of Ezetimibe lowers total and low-density lipoprotein cholesterol in hypercholesterolemic dogs with hyperadorenocorticism.
- Source :
-
The Journal of veterinary medical science [J Vet Med Sci] 2024 Apr 01; Vol. 86 (4), pp. 363-367. Date of Electronic Publication: 2024 Feb 22. - Publication Year :
- 2024
-
Abstract
- Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of both biliary and dietary cholesterol, thereby lowering primarily low density lipoprotein-cholesterol (LDL-chol) in human studies. This study aimed to investigate the effects of ezetimibe on dyslipidemia control in nine dogs with hypercholesterolemia. Changes in total cholesterol (T-chol) and each lipoprotein fractions were evaluated at 0, 2, and 4 months following initiation of ezetimibe treatment. A significant decrease in T-chol was observed, and a mean T-chol concentration below 400 mg/dL was achieved at 2 and 4 months. Furthermore, a significant decrease in LDL-chol was observed (-53.3% and -64.3% at 2 and 4 months, respectively). Taken together, treatment of ezetimibe could lower LDL-chol levels in dogs with hypercholesterolemia.
Details
- Language :
- English
- ISSN :
- 1347-7439
- Volume :
- 86
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- The Journal of veterinary medical science
- Publication Type :
- Academic Journal
- Accession number :
- 38383002
- Full Text :
- https://doi.org/10.1292/jvms.23-0461